Taste masked microspheres of ofloxacin: formulation and evaluation of orodispersible tablets

Karan Malik1, Gurpreet Arora, Inderbir Singh

  • 1School of Pharmaceutical Sciences, Chitkara University, Solan-174103, Himachal Pradesh, India.

Scientia Pharmaceutica
|September 3, 2011
PubMed

Insights

This study developed taste-masked ofloxacin microspheres using Eudragit and locust bean gum orodispersible tablets to improve patient compliance by overcoming the antibiotic's unpleasant taste.

Area of Science:

  • Pharmaceutical Technology
  • Drug Delivery Systems
  • Materials Science

Background:

  • Ofloxacin is an antibiotic effective against bacterial infections.
  • Poor patient compliance is linked to ofloxacin's bitter taste.
  • Taste masking is crucial for improving oral drug administration.

Purpose of the Study:

  • To develop taste-masked ofloxacin microspheres using Eudragit E100.
  • To formulate these microspheres into orodispersible tablets using locust bean gum.
  • To evaluate the efficacy of taste masking and tablet properties.

Main Methods:

  • Ofloxacin microspheres were prepared via solvent evaporation technique using Eudragit E100.
  • Differential Scanning Calorimetry (DSC) was used to assess drug-polymer interactions.
  • Orodispersible tablets were formulated incorporating locust bean gum as a natural superdisintegrant.

Main Results:

  • Entrapment efficiency of microspheres ranged from 69.54% to 86.52%.
  • Optimal drug/polymer ratios (1:4, 1:5) demonstrated good flow and taste masking.
  • Orodispersible tablets exhibited rapid disintegration (10-22 seconds) and high drug release (>97% in 2 hours).

Conclusions:

  • Eudragit E100 effectively masks the bitter taste of ofloxacin.
  • Locust bean gum serves as a suitable natural superdisintegrant for orodispersible tablets.
  • This formulation approach enhances patient compliance for ofloxacin therapy.

Related Concept Videos

Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
Oral Drug Delivery Systems: Introduction01:23

Oral Drug Delivery Systems: Introduction

Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Factors Affecting Dissolution: Particle Size and Effective Surface Area01:23

Factors Affecting Dissolution: Particle Size and Effective Surface Area

Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are employed to...